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Activation Likelihood Estimation Meta-Analysis of 
Brain Correlates of Placebo Analgesia in Human 
Experimental Pain
Martina Amanzio, Fabrizio Benedetti, Carlo A. Porro, 
Sara Palermo, and Franco Cauda
Abstract: Placebo analgesia (PA) is one of the most studied placebo effects. Brain imaging studies pub­
lished over the last decade, using either positron emission tomography (PET) or functional magnetic 
resonance imaging (fMRI), suggest that multiple brain regions may play a pivotal role in this process. 
However, there continues to be much debate as to which areas consistently contribute to placebo anal- 
gesia-related networks. In the present study, we used activation likelihood estimation (ALE) meta-anal- 
ysis, a state-of-the-art approach, to search for the cortical areas involved in PA in human experimental 
pain models. Nine fMRI studies and two PET studies investigating cerebral hemodynamic changes 
were included in the analysis. During expectation of analgesia, activated foci were found in the left an­
terior cingulate, right precentral, and lateral prefrontal cortex and in the left periaqueductal gray 
(PAG). During noxious stimulation, placebo-related activations were detected in the anterior cingulate 
and medial and lateral prefrontal cortices, in the left inferior parietal lobule and postcentral gyrus, an­
terior insula, thalamus, hypothalamus, PAG, and pons; deactivations were found in the left mid- and 
posterior cingulate cortex, superior temporal and precentral gyri, in the left anterior and right posterior 
insula, in the claustrum and putamen, and in the right thalamus and caudate body. Our results sug­
gest on one hand that the modulatory cortical networks involved in PA largely overlap those involved 
in the regulation of emotional processes, on the other that brain nociceptive networks are downregu- 
lated in parallel with behavioral analgesia.
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INTRODUCTION
Placebo analgesia (PA) is one of the best-studied placebo 
effects. The neurobiology of PA was bom with the discov­
ery that the opioid receptor antagonist naloxone can 
reverse PA in clinical and experimental pain [Benedetti, 
1996; Levine et al., 1978]. Other studies suggest that en­
dogenous opioids are not the only neurochemicals 
involved in PA. Indeed, nonopioid mechanisms have also 
been described, particularly in the context of previous pre­
conditioning with nonopioid agents [Amanzio and Bene­
detti, 1999]. Many brain systems besides the endogenous 
opioid system may contribute to the placebo effect, such 
as the dopamine reward system [Scott et al., 2007, 2008].
The advent of brain imaging tools provided neuroscient­
ists with a window into the brain activity orchestrating PA. 
Specifically, functional magnetic resonance imaging (fMRI) 
studies of blood oxygen level-dependent (BOLD) signals or 
positron emission tomography (PET) studies of regional 
cerebral blood flow (rCBF) or neurochemical changes have 
enabled researchers to study changes in neural activity in 
experimental placebo paradigms. Placebo effects can be 
mediated by increased descending modulation via brain­
stem inhibitory systems and activation of endogenous 
opioid systems, which can lead to changes in the affec­
tive/-motivational dimension of pain processing through 
the activation of cortical regions such as the anterior cingu- 
late cortex (ACC) and the dorsolateral and orbitofrontal/- 
ventrolateral prefrontal cortices (DLPFC, OFC, and VLPFC 
respectively; for review, see Benedetti et al. [2005]). In par­
ticular, the DLPFC cortex has been proved to be consis­
tently associated with cognitive control of representation 
and maintenance of information, consistent with a role in 
expectation [Miller and Cohen, 2001]. Because the activa­
tion of both the DLPFC and OFC is correlated with brain­
stem activation in placebo expectation [Wager et al., 2004], 
the PFC may trigger PA responses through activation of 
other pain modulatory regions besides the ACC, including 
the thalamus and brainstem areas such as the periaqueduc­
tal gray (PAG) and rostral ventromedial medulla.
Importantly, Kong et al. [2006] underline that multiple 
pathways and mechanisms may explain the apparent 
inconsistencies in placebo imaging studies. One reason for 
the diverging evidence on the involvement of different 
brain regions in placebo-related networks is represented 
by the heterogeneity of the experimental designs, such as 
pain paradigms and the degree of certainty associated 
with pain relief expectations [Ploghaus et al., 2003].
To identify human brain regions that are consistently 
implicated in placebo analgesia, we adopted a coordinate- 
based meta-analysis approach (activation likelihood esti­
mation; ALE), which is considered to be the best method 
to search for the cortical areas implicated in the phenom­
enon of interest [Eickhoff et al., 2009; Salimi-Khorshidi 
et al., 2009].
The aim of this study is to provide a quantitative meta­
analysis of the neuroimaging literature—using PET and
fMRI to investigate cerebral hemodynamic changes—in 
order to delineate consistent activation of brain regions 
associated with PA in human experimental pain. Deactiva­
tion foci related to PA are also considered here in a sepa­
rate analysis from that used to study activation sites. The 
neural correlates of PA were investigated through two dif­
ferent analyses, aimed at assessing changes occurring ei­
ther during expectations of analgesia or during noxious 
stimulation.
MATERIALS AND METHODS
Literature Search, Selection, and 
Methodological Challenges
We followed the guidelines for meta-analyses and sys­
tematic reviews of observational studies, MOOSE [Stroup 
et al., 2000].
A systematic search strategy was used to identify rele­
vant studies, published on or before November 1, 2010, 
across the online database most frequently used in the 
international literature (Medline database with Pubmed lit­
erature search: www.pubmed.org; see also the PubAtlas 
search included in the Supporting Information).
All studies that included one of the following terms 
were considered: "Pain"; "Placebo effect"; "fMRI"; "PET."
We also searched published meta-analyses and reviews 
on PA to identify additional studies using the above-men­
tioned neuroimaging techniques, which were not included 
in the Pubmed literature search database. The references 
included in the reviews identified in these searches were 
used as an additional source to identify other studies.
All articles were reviewed to establish that (1) the exper­
imental pain paradigms included a baseline condition, in 
order to study functional activity during PA minus resting 
state conditions; (2) the results were reported in Talair- 
ach/Tournoux or in Montreal Neurological Institute (MNI) 
coordinates; (3) the field of view was not confined to a re­
stricted region of the cortex [Radua and Mataix-Cols, 2009; 
Radua et al., 2010] (4) the studies reported cerebral hemo­
dynamic changes, as assessed by BOLD-fMRI or rCBF- 
PET.
We also tried to identify any instances of multiple 
reports of single data sets across articles to ensure that 
only one report of a study contributed to the coordinates 
for the present meta-analysis. This assertion is true for all 
the selected studies, except for those by Price et al. [2007] 
and Craggs et al. [2008]; although both refer to the same 
experimental design and the same group of patients, the 
former reports deactivation foci, the latter the activation 
foci related to placebo analgesia.
The focus of our study was on PA in human experimen­
tal pain paradigms. However, two studies (described in 
three of the selected papers: Craggs et al., 2008; Price 
et al., 2007; Lu et al., 2010) considered patients, who 
were suffering either from irritable bowel syndrome
(IBS; 11 — 9) or from functional gastrointestinal disorder 
(FGID; n =  14). Although IBS and FGID can cause 
discomfort, they do not harm the intestines or lead to 
any serious disease (see the Digestive Diseases Dictionary 
at www.digestive.niddk.nih.gov/index.html). Besides, as 
stated by Lu et al. (2010), none of the 14 FGID patients 
were taking drugs affecting gastrointestinal motor func­
tions or pain perception. Finally, in all studies considered 
for the present meta-analysis, PA did modulate experi­
mentally induced pain, rather than spontaneous ongoing 
pain. On these grounds, we believe that it is appropriate 
to include the results from the three above-mentioned 
papers in our meta-analysis.
Studies were independently ascertained and checked by 
two of the authors for any discrepancies, which were 
resolved by a third author. In four cases (Craggs, Kong, 
Nemoto, and Petrovic), we contacted authors to avoid any 
errors in our interpretation of the experimental conditions 
and/or of the functional significance of the foci identified 
in the studies (all the authors kindly replied and resolved 
our doubts).
Following the suggestions of Rainville and Duncan
[2006] in terms of methodological challenges and recom­
mendations in experimental studies on PA, we carefully 
checked the conditions and experiments, placebo induc­
tion, pain assessment, possible selection of placebo res­
ponders, and the brain mechanisms related to PA. 
Descriptive information was extracted from each article 
including imaging and experimental modality, sample 
size, and pain stimulus attributes, such as modality, loca­
tion (site, side), and duration. Tables I and II provide a 
detailed description of the methods used in the selected 
studies. A fixed-intensity paradigm was defined as an 
experiment that used the same level of stimulation for all 
participants, whereas a subject-dependent paradigm was 
defined as an experiment that used different stimulus 
intensities among subjects. In the latter paradigm, the in­
tensity of stimuli used was individually determined by a 
prescan scaling procedure [Farrel et al., 2005].
The number of activation and deactivation foci was also 
established for each study.
We also checked the phase in which the placebo-related 
brain activity had been studied, considering the three tem­
poral stages of PA as defined by Kong et al. [2007] (Fig. 1):
• Stage 1: Expectation/anticipation: Before the pain 
starts, expectation or anticipation of pain relief could 
modulate perception of the subsequent pain stimuli. In 
an fMRI paradigm, this corresponds to the period of 
"expected analgesia" [period of time between the be­
ginning of the scan (or of each trial, in event-related 
fMRI paradigms), and the beginning of the stimulus].
• Stage 2: Noxious stimuli administration: During 
administration of painful stimuli, placebo treatment 
linked with previous knowledge about analgesic 
effects could inhibit the incoming signals of noxious 
stimuli. In particular, this component is related to
brain activity between the beginning of the stimulus 
and its termination.
• Stage 3: Subjective pain intensity rating (appraisal of 
pain). After the pain stimulus has ended, previous 
knowledge of treatment effect may unconsciously dis­
tort subjective pain rating.
Table I also represents studies in terms of placebo- 
related activity during stages 1, 2, and 3 of analgesia (see 
Fig. 1). Six of eleven studies assessed alterations in stage 1 
[Eippert et al., 2009a; Lu et al., 2010; Lui et al., 2010; Study 
1 and 2 by Wager et al., 2004; Watson et al., 2009]. Ten of 
eleven studies assessed PA in the second stage condition 
[Bingel et al., 2006; Craggs et al., 2008; Eippert et al., 
2009a; Kong et al., 2006; Lu et al., 2010; Lui et al., 2010; 
Petrovic et al., 2002; Price et al., 2007; Study 1 and 2 by 
Wager et al., 2004; Watson et al., 2009]. Two of eleven 
studies assessed PA also in the third stage condition [Eip­
pert et al., 2009a; Nemoto et al., 2007].
In particular, Wager et al. [2004] sought to discriminate 
the activity induced by PA in the anticipation of pain from 
changes registered during pain experience. In the study by 
Kong et al. [2006], placebo acupuncture treatment was 
accompanied by analgesic expectations that were manipu­
lated by lowering the temperature in the placebo side of 
the arm but not in the control side, causing the partici­
pants to experience analgesia. The study by Nemoto et al.
[2007] investigated the last stage of PA in which partici­
pants were classified as responders or nonresponders 
based on subjective reports of reactions to painful stimuli 
after 7 days of pill placebo administration. The study by 
Eippert et al. [2009a] analyzed PA considering each of the 
three stages. Last, the study by Lui et al. [2010] investi­
gated placebo-related brain activity during stage 1 of anal­
gesia (as compared to anticipation of pain) and during 
stage 2, in a model of conditioned placebo analgesia. All 
the other studies reported data in the second stage condi­
tion; on the other hand, Lu et al. [2010] also considered 
placebo-related brain activity during stage 1 of analgesia.
We performed here two different analyses. In the first, 
we examined the neural changes related to prestimulation 
pain expectation of analgesia (stage 1 of the PA compo­
nents in the model represented in Fig. 1), whereas in the 
second, we analyzed the changes in brain activity occur­
ring during noxious stimulation (stage 2 in the model rep­
resented in Fig. 1).
Because of the paucity of data in the literature, we did 
not examine neural changes occurring during stage 3 or 
during placebo conditioning. In particular, the only paper 
where stages 2 and 3 were somehow intermingled is that 
by Nemoto et al. [2007]. However, because stimulation 
was continued throughout the acquisition scans, we 
believe that their results can be attributed to the stage 2. 
The foci of the study by Eippert et al. [2009a] referring to 
stage 3 were instead not considered in our analysis.
We used automated GingerALE 2.0 routines [Eickhoff 
et al., 2009; Laird, 2009] to convert MNI coordinates into
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Placebo treatment can target each of the three stages described 
in the figure and the final outcome o f pain. The treatment is 
considered as a function o f time. [C o lor figure can be viewed in 
the online issue, which is available at wileyonlinelibrary.com.]
Talairach/Tournoux space using the icbm2tal transform 
[Lancaster et al., 2007]. Importantly, the findings of Lancaster 
et al. [2007] show that MNI/Talairach coordinate bias associ­
ated with reference frame (position and orientation) and scale 
(brain size) can be substantially reduced using the best-fit 
icbm2tal transform.
Coordinate-Based Meta-Analysis
Quantitative meta-analysis techniques, such as ALE [Tur- 
keltaub et al., 2002], provide information about the anatomi­
cal reliability of the results reported in a collection of related 
studies within the existing literature. ALE meta-analysis is a 
quantitative voxel-based meta-analysis method that can be 
used to estimate consistent activation across different imag­
ing studies [Laird et al., 2005]. This method does not rely 
upon author-assigned anatomical labels; rather, it requires 
only that activation foci be reported in standard stereotactic 
space [Laird et al., 2005]. During an ALE analysis, each acti­
vation focus from each article is modeled as the center of a 
Gaussian probability distribution. These 3D Gaussian distri­
butions are subsequently summed to create a statistical map 
that estimates the likelihood of activation for each voxel as 
determined by the entire set of studies. This map is then 
thresholded using permutation testing as proposed by the 
authors of the ALE methodology (Laird et al., 2005; Lancas­
ter et al., 2000, 2007) and with reference to the literature on 
this matter (see www.brainmap.org).
ALE activation maps are usually derived on the basis of 
foci of interest, where multiple studies have reported stat­
istically significant peak activation locations. To limit the 
intersubject and interlaboratory variability typical of neu­
roimaging studies, we used an algorithm that estimates 
the spatial uncertainty of each focus taking into account 
the possible differences among studies related to sample 
size [Eickhoff et al., 2009]. This algorithm was preferred to 
a prespecified FWHM as in the original ALE approach. 
The advantage of such an algorithm is that it comprises a 
method to calculate the above-chance clustering between 
experiments (i.e., random effects analysis, RFX), rather 
than between foci (fixed effects analysis, FFX) [Eickhoff 
et al., 2009]. Accordingly, to improve the output, we per­
formed an accurate coordinate transformation using the 
most recent and unbiased method [Eickhoff et al., 2009].
ALE maps were computed using a Java-based version of 
ALE software named GingerALE (version 2.0.4) at an FDR- 
corrected threshold of P <  0.05 and a minimum cluster size 
of K >  50 mm3. This software requires the coordinates to be 
provided in Talairach space and produces its output in 
the same standard. ALE maps were then visualized using 
Mricron (http://www.cabiatl.com/mricro/mricron/index. 
html) and BrainVoyager QX 2.2 [Goebel et al., 2006].
The location of clusters in the Talairach space was 
assigned by identifying the location of the coordinates of 
the maximum ALE value using the Talairach Daemon 
(http://www.talairach.org/) [Lancaster et al., 2000]. Each 
label was provided automatically by the program. Because 
important areas related to pain and placebo may fall 
within areas where the Talairach Daemon has insufficient 
coverage (e.g., pons and brain stem), we identified these 
locations separately using the "Duvernoy's Atlas of the 
Human Brain Stem and cerebellum" [Naidich et al., 2009].
Jackknife Analysis
To rule out the possibility of some activations being driven 
by the contribution of a small subset of studies, we per­
formed a jackknife analysis. The jackknife is a nonparametric 
method for estimating the sampling distribution of a statistic 
[Fan and Wang, 1996; Radua and Mataix-Cols, 2009; Radua 
et al., 2010; Wu, 1986; Shao and Tu, 1995]. Given a sample 
data set and a desired statistic (e.g., the mean), the jackknife 
works by computing the desired statistic with an element (or 
a group of elements) deleted. This is done for each element of 
the data set. The collection of these statistics is used as an 
estimate of the sampling distribution. A radar plot of the 
sampling distribution is usually performed on the computed 
values of the statistic [Fan and Wang, 1996; Wu, 1986].
RESULTS
The studies that were excluded are listed in the appen­
dix in the Supporting Information along with the reason 
for their exclusion. In particular, we excluded 43 fMRI 
studies and 21 PET studies (see the trial flow represented 
in the Graph 1).
Graph I.
Trial flow: Selection of study reports (see Appendix I fo r more details).
The characteristics of the 11 studies (reporting nine 
experiments with BOLD-fMRI and two experiments with 
rCBF-PET), designated as suitable for meta-analysis, are 
reported in Table I. They included the studies described in 
the work by Wager et al. [2004], which analyzed two ex­
perimental sessions and were consequently coded as two 
reports, and the works by Price et al. [2007] and Craggs 
et al. [2008], which are based upon the same experiments 
(see Methods section). Together, these studies include data 
from 199 subjects (154 for fMRI and 45 for PET paradigms) 
and report 159 activation and 46 deactivation foci. Most
studies explored pain-related brain activity using fMRI 
(81.81%) in healthy subjects (86.43%) and used contact 
noxious heat stimuli (36.36%) or laser noxious heat stimuli 
(36.36%). The remaining 18.18% of the studies used rectal 
balloon or esophageal balloon distension.
The 11 experiments yielded tabulated coordinates for 36 
contrasts involving left-side stimulation and 98 contrasts for 
right-side stimulation. The ALE analysis of the left side incor­
porated 118 foci and the right analysis 87 foci. The labels 
ascribed to the activation sites by the authors of the studies 
are summarized in the Supporting Information Table I.
The average age of the samples (calculated from 9 stud­
ies) was 28.18 years (see Table II). Manual dominance was 
only specified for 76.88% of cases; most subjects were 
right-handed (96.73%). There was a lack of information 
about gender for 32.66% of our sample. The remaining 
36.18% were men, while 31.15% were women. About 
86.43% of the samples were healthy.
Clusters of Neural Activity Changes
The brain regions identified in the meta-analysis are pre­
sented in Tables III-V.
PA-related changes during prestimulation pain 
expectation (stage I)
Expectation component cluster analysis for stage 1 of 
PA identified three clusters with a volume of more than 
200 mm3 where there was increased placebo-related activ­
ity compared to baseline values. These included the right 
precentral gyrus and the left ACC.
Two clusters with volumes exceeding 50 mm3 were 
located in the right rostral prefrontal cortex and the left 
periacqueductal gray (Table III and Figs. 2 and 3).
PA-related changes during noxious 
stimulation (stage 2)
The noxious stimulation cluster analysis identified five 
clusters with a volume of more than 300 mm3 showing 
increased PA activity compared to baseline values. These 
included the left medial dorsal nucleus of the thalamus, 
the bilateral rostral ACC (rACC), and the pons. Five other 
clusters with a volume of more than 200 mm3 exhibited a 
network of co-activated regions including the anterior 
insula, the periacqueductal gray, the parahippocampal 
gyrus, the inferior parietal lobule (all of which were more 
left lateralized), and the orbito-frontal area with a right lat­
eralization. Another cluster with a volume of more than 
100 mm3 was the left postcentral gyrus (Table IV).
Two clusters of decreased PA activity with a volume of 
more than 600 mm3 were found in the claustrum, in the 
putamen, and in the posterior cingulate, all of which were 
more left lateralized. Two other clusters of deactivation 
with a volume more than 300 mm3 were seen in the left 
superior temporal gyrus. Other clusters with a volume 
more than 100 mm3 were seen in the left mid-cingulate 
cortex, in the right caudate body, and putamen. Smaller 
clusters were found in the left anterior insula and in the 
right posterior insula (Table V and Figs. 4 and 5).
Reliability of the Identified Clusters: Jackknife 
Analysis
The jackknife analysis described in the Methods section 
allowed us to affirm the validity of the results obtained
through the ALE methodology. Indeed, no identified blob 
was driven by a single paper, and reliability was > 50%, 
for all clusters (see Fig. 6 and Figs. A and B of the Sup­
porting Information).
DISCUSSION
The goal of this coordinate-based ALE meta-analysis was 
to quantitatively analyze the results of neuroimaging stud­
ies investigating cerebral hemodynamic changes, aiming to 
investigate the neural correlates of placebo analgesia. Our 
study represents the first attempt to consider all the data 
from the literature in a single analysis, in order to provide a 
more objective overall perspective. Meta-analyses are prone 
to selection biases, although we tried to control as many fac­
tors as possible [Rainville and Duncan, 2006]. Importantly, 
by performing different analyses, we were able to consider 
the neural changes related to expectations of analgesia sepa­
rately from those concerning PA-related changes during the 
noxious stimulation (see Methods section).
Notably, our study represents the first attempt to sum­
marize the brain areas involved in PA in human experi­
mental pain. Despite the small number of studies suitable 
for inclusion, our analyses identified significant ALE clus­
ters, which were broadly consistent with the proposed 
regions involved in PA in human experimental pain. 
Indeed, altogether, these studies included data from 199 
subjects (154 for fMRI and 45 for PET paradigms) and 
reported 162 activation and 46 deactivation foci. These 
numbers were sufficient for us to objectively proceed with 
the ALE analysis (as stated by Laird in his "Users' Manual 
for BrainMap Ginger ALE 2.0"). Moreover, as seen in Fig­
ure 6, none of the "blobs" that we identified through our 
analyses could be deemed to have been guided by a single 
work. On the basis of the Jackknife analysis findings, we 
can state that even the use of a small number of works 
does not lead to spotty results.
From this evidence, we can now draw a possible theo­
retical explanation of placebo analgesia.
During noxious stimulation, we observed an increased 
activity in the ACC, the insula, and the diencephalon (the 
thalamus and the hypothalamus) as well as in brainstem 
regions such as the PAG and pons, whose involvement in 
descending and specifically the opioid analgesia is well 
established [Yaksh, 1997]. Descending influences from the 
ACC, insular and prefrontal cortex and diencephalon that 
elicit inhibition or facilitation of nociceptive transmission 
via brainstem structures are now thought to occur during 
PA (see the review of Tracey and Mantyh [2007]).
Conversely, we demonstrate that PA is accompanied by 
decreased activity in some portions of the pain matrix 
[Melzack, 1999; Tracey and Mantyh, 2007], such as the 
mid-cingulate cortex and the anterior and posterior insula, 
as well as in the basal ganglia. Because placebo-induced 
decreases were detectable during noxious stimulation, 
they are likely to reflect actual reduction of nociceptive
T A B LE  III. Areas of increased activity associated with placebo analgesia during stage l a
Cluster no. Volume (mm3) X Y Z Hemisphere Label BA
1 520 38 0 32 R Precentral gyrus 6
2 328 - 8 38 - 2 L rACC
3 248 - 6 22 30 L Anterior mid-cingulate 32
4 80 26 44 0 R Lateral prefrontal cortex 10
5 64 - 2 -2 6 -1 0 L PAG
“Stage 1 (prestimulation pain expectation).
L, left; R, right; BA, Brodmann area; PAG, periaqueductal gray; rACC, rostral anterior cingulate.
T A B LE  IV. A re a s  o f  increased a c t iv ity  associa ted w ith  p lacebo analgesia d u rin g  stage 2a
Cluster no. Volume (mm3) X Y Z Hemisphere Label BA
1 640 - 4 -1 4 12 L Medial dorsal nucleus
2 512 18 8 40 R rACC 32
3 328 0 36 16 L rACC 32
4 312 - 6 -3 0 -3 2 L Pons
5 288 -5 0 -1 0 12 L Anterior insula 13
6 280 - 4 -3 4 -1 6 L PAG
7 272 -1 2 -3 0 - 4 L Parahippocampal gyrus 30
8 232 -5 8 -2 6 24 L Inferior parietal lobule 40
9 208 0 40 -1 8 R Orbito-frontal area 11
10 176 -6 6 -1 4 24 L Postcentral gyrus 1
11 64 -1 4 -3 8 -3 8 L Pons
12 64 -2 2 38 34 L DLPFC 9
13 64 -4 0 -2 6 52 L Postcentral gyrus 3
14 56 - 6 - 2 -1 2 L Hypothalamus
15 56 - 2 -1 0 48 L Medial frontal gyrus 6
“Stage 2 (start and end of noxious stimuli administration). L, left; R, right; BA, Brodmann area; DLPFC, dorsolateral prefrontal cortex; 
PAG, periaqueductal gray; rACC, rostral anterior cingulate.
T A B LE  V. A rea s  o f  decreased a c t iv ity  associa ted w ith  p lacebo analgesia d u rin g  stage 2a
Cluster no. Volume (mm3) X Y Z Hemisphere Label BA
1 1256 -3 4 0 - 2 L Claustrum
-2 6 10 - 2 L Putamen
2 608 - 6 -1 8 46 L Posterior cingulate 31
3 328 -4 0 -2 0 2 L Superior temporal gyrus
4 320 -5 2 -3 0 20 L Superior temporal gyrus 41
5 272 - 2 6 32 L Mid-cingulate 24
6 128 16 4 12 R Caudate body
22 4 18 R Putamen
7 80 -3 8 -1 0 - 6 L Subgyral 21
8 80 56 -3 8 20 R Posterior insula 13
9 64 2 -1 6 12 R Medial dorsal nucleus
10 64 -5 6 - 6 12 L Precentral gyrus 43
11 56 36 - 6 - 6 R Claustrum
12 56 -4 2 - 4 8 L Anterior insula 13
“Stage 2 (start and end of noxious stimuli administration). L, left; R, right; BA, Brodmann area.
F igu re  2.
Areas o f increased activity associated w ith placebo analgesia in the expectation stage I and dur­
ing noxious stimulation stage 2. Areas o f decreased activity associated w ith placebo analgesia in 
stage 2 are also shown. ALE maps were computed using GingerALE 2.0.4 at an FDR-corrected 
threshold o f P <  0.05, w ith a minimum cluster size o f K >  50 mm3 and visualized using MRIcron. 
They were projected onto a 3D rendering model o f the brain.
F igu re  3.
Areas o f increased activity associated w ith placebo analgesia in the expectation stage I . ALE 
maps were computed using GingerALE 2.0.4 at an FDR-corrected threshold o f P < 0.05, with a 
minimum cluster size o f K >  50 mm3 and visualized using MRIcron.
F igu re  4.
Areas o f increased activity associated with placebo analgesia during noxious stimulation stage 2. 
ALE maps were computed using GingerALE 2.0.4 at an FDR-corrected threshold of P < 0.05, 
w ith a minimum cluster size o f K >  50 mm3 and visualized using MRIcron.
F igu re  5.
Areas of decreased activity associated w ith placebo analgesia during noxious stimulation stage 2. 
ALE maps were computed using GingerALE 2.0.4 at an FDR-corrected threshold of P < 0.05, 
w ith a minimum cluster size o f K >  50 mm3 and visualized using MRIcron.
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F igu re  6.
Reliability o f increased activity associated with placebo analgesia in stage I (A ) and in stage 2 (B). 
In (C), reliability o f decreased activity associated with placebo analgesia in stage 2.
processing, rather than modulation of the cognitive evalua­
tion of pain intensity. Indeed, there is preliminary evi­
dence that placebo-induced antinociceptive effects can be 
identified in the spinal cord [Eippert et al., 2009b],
although confirmatory data are required in this regard. 
The lack of consistent deactivation in the somatosensory 
cortices is conceivably related to the different body sites 
and stimuli employed in the different studies.
Altogether, these results lend further support to the hy­
pothesis that PA is based at least in part upon changes in 
actual processing of nociceptive information and, there­
fore, in pain perception [Lui et al., 2010; Price et al., 2007], 
although additional components cannot be ruled out.
Other interesting insights about the mechanisms of PA 
can be gained by focusing on changes in brain activity that 
take place during the expectation phase (stage 1). In fact, 
expectation of benefit can induce a placebo effect even 
without the physical administration of a placebo. Because 
no placebo is actually given, these effects may be more 
appropriately called "placebo-like" effects. Thus, activity in 
pain areas following an identical painful stimulus can 
be modulated just by varying the subject's expectation of 
the level of stimulation: the higher the expected level of the 
stimulus, the stronger the activity, that is, in the ACC and 
the PAG and other areas implicated in the activation of the 
descending inhibitory pathway [Koyama et al., 2005]. 
Indeed, it has been shown that the activation of the same 
neurotransmitter systems in the brain can be obtained by a 
pharmacological (drug) or a psychological (placebo) means 
[Zubieta and Stohler, 2009]. As far as the expectation of an­
algesia network was concerned, we observed an increased 
activity associated with PA in areas such as the ACC and 
the PAG. Interestingly, an area selectively activated in the 
PA expectation component and not present when we ana­
lyzed the PA during noxious stimulation is BA10, demon­
strating that anticipatory responses may well be part of a 
more general mechanism that is not confined to pain. This 
area is considered as a cognitive control region and one of 
the most fascinating puzzles in cognitive neuroscience [Bur­
gess et al., 2005]. It is consistently implicated in tasks where 
one has to "bear something in mind" whilst doing some­
thing else, for example, voluntary task switching after a 
delay [e.g., Koechlin et al., 1999], prospective memory [Bur­
gess et al., 2001, 2003; Okuda et al., 1998], and "monitoring" 
type tasks [e.g., MacLeod et al., 1998]. Thus, the characteri­
zation of the rostral processing system as cross-domain 
[Burgess et al., 2003] and serving the purpose of guiding 
behavior in situations where the optimal course of action is 
not obvious or established seems secure [Burgess et al., 
2000; Goel and Grafman, 2000; Pollman, 2004]. In particu­
lar, an analysis of context, in terms of cognitive flexibility, 
prospective memory, monitoring, and executive attention 
abilities, appears to indicate different responses in the 
working memory counterpart [Damasio, 1996; Wager et al., 
2004], a particular condition impaired in AD patients 
[Amanzio et al., 2011], in which loss of expectancy mecha­
nisms disrupts PA and thus makes analgesic therapies less 
effective [Benedetti et al., 2006].
The results of both our analyses demonstrate how the 
areas engaged by PA in human experimental pain may be 
part of a general circuit underlying the voluntary regula­
tion of affective responses [Bechara et al., 1997; Damasio, 
1996; Petrovic et al., 2005; Wager et al., 2011].
Apart from the involvement of similar regions in the 
processing of pain and emotion, both PA [Lieberman 
et al., 2004; Petrovic and Ingvar, 2002; Wager et al., 2004]
and emotional regulation [Bishop et al., 2004; Ochsner 
et al., 2002] are associated with increased activation in a 
modulatory network that includes the rACC and prefron- 
tal cortices. This suggests a functional-anatomical relation­
ship between PA and emotional regulation in which top- 
down modulation of the pain or emotional network is 
implemented. We suggest that the placebo phenomenon 
may be applied to any emotional experience, in terms of a 
reduction in negative emotions; indeed, our data demon­
strate the involvement of a modulatory array of brain 
regions very near to those observed by Petrovic et al. 
[2005] in the emotional placebo.
CON CLUSION S
The present data suggest that pain perception may be 
reduced through a placebo treatment by networks similar 
to those described for the modulation of emotional experi­
ence and the anticipation of therapeutic benefit [Petrovic 
et al., 2005].
Indeed, both PA [Lieberman et al., 2004; Petrovic et al., 
2002; Wager et al., 2004] and emotional regulation [Bishop 
et al., 2004; Ochsner et al., 2002] are associated with 
increased activation in the ACC, the lateral prefrontal and 
orbitofrontal cortices, the periaqueductal gray, and with 
decreased activation of the regions involved in mood 
changes, thus suggesting a role of anxiety reduction 
through the placebo treatment. This points to a functional- 
anatomical relationship between PA and emotional regula­
tion in which a top-down modulation of the pain or emo­
tional network is implemented.
Specifically, PA analgesia is accompanied by decreased 
activation in some regions of the pain matrix during nox­
ious stimulation. These findings point to a true antinoci­
ceptive effect associated with placebo analgesia, in 
addition to its potential modulation of cognitive evaluation 
of pain intensity.
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